Search results

Examines wealth effects of the Drug Price Competition and Patent Term Restoration Act of 1984 in the United States. Historical background on the legislation; Sequence of events leading to the passage of the law; Economic significance of the law.

We consider a dynamic competition game involving three players, in which each player can vary the extent of his competition on a per-rival basis. We call such competition targeted. We show that if the players are myopic, then the weaker players eventually lose the game to their strongest rival. If instead the players are sufficiently far-sighted, then all three players converge in their power and stay in the game. We develop our model in application to drug wars, but the approach of targeted competition can be applied to competition between firms or political parties, or to warfare.

After describing the intellectual property and regulatory environment for orphan drugs in the United States, this thesis compares the investment decisions in the orphan drug market with the larger pharmaceutical industry. A series of case studies trace the development paths of different orphan products using information collected through the Food and Drug Administration (FDA) Approved Drug Product and Orphan Drug Product Designation Databases. In addition to this analysis, difference-in-differences estimates calculated using annual revenues compare the relative success of different orphan products under the current incentive system. This study finds that partial orphan drugs are associated with larger revenue growth. Lastly, this study proposes several policy prescriptions as alternatives to the current legislation.

Shipping list no.: 99-0269-P. ; "As amended, February 1998." ; Cover title. ; Mode of access: Internet.

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (generally referred to as the Medicare Modernization Act, or MMA) substantially expanded the federal Medicare program by creating the prescription drug benefit known as Part D. In fiscal year 2013, Medicare Part D covered 39 million people. The federal government spent 59 billion net of premiums on Part D in that year; after accounting for certain payments from states under the program, the net federal cost was 50 billion, which represented 10 percent of net federal spending for Medicare. This book discusses the cost tr

After numerous attempts over more than a decade, the Philippine government finally enacted a comprehensive competition law, the Philippine Competition Act (Republic Act 10667) in July 2015. Before this breakthrough legislation, competition policy and law was scattered in about 30 different laws (for instance, the Philippine Constitution, Revised Penal Code, Consumer and Price Acts, and sector-specific regulations), with outdated provisions and hardly any jurisprudence. The passing of the law is only the first step. Much needs to be done to establish a truly working competition policy, including capacity building, and dissemination, information, and education for the law. This paper attempts to contribute in this regard by examining the provisions of the new law and providing an overview of what it covers, what it can do, and what could be the possible implications for related policies. As such, this paper has three major sections. The first provides an overview of the rationale and objectives of competition law. The second discusses the major provisions of the new law, including some comments to highlight important provisions. The third section provides an overall assessment of the act and additional comments and observations. The section also briefly looks at the case of PLDT/Globe acquisition of the San Miguel Corporation's telecommunications assets.

Digest of relevant court opinions handed down since 1933. ; Part of a project to supplement: United States. Dept. of Agriculture. Office of the General Counsel. Decisions of courts in cases under the Federal Food and Drugs Act. ; Mode of access: Internet.